siponimod

October 30, 2017October 30, 2017

#MSParis2017 – Promising Work in Pediatric and Secondary Progressive Patients Is Focus, Novartis Says in Interview

News

Gilenya (fingolimod) lowered relapse rates in children and adolescents with relapsing multiple sclerosis at a “magnitude” — almost 82 percent — never before seen in a ... Read more

October 26, 2017October 27, 2017

#MSParis2017 – Siponimod Leads to Dramatic Drop in MS Lesions, Phase 3 Trial Shows

News

Novartis’ Siponimod led to a dramatic drop in the number of inflammation patches in the brains and spinal cords of secondary progressive multiple sclerosis patients, according to a ... Read more

June 2, 2017June 2, 2017

#CMSC17 – Ocrevus, Progressive MS and Other Research Highlights: An Interview with CMSC’s Robert Lisak

News

The recent annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) brought researchers and healthcare professionals to New Orleans to discuss advances — and obstacles to advances ... Read more

April 28, 2017April 28, 2017

Siponimod Slows Progression of MS Disability, Phase 3 Clinical Trial Shows

News

Siponimod slows the progression of multiple sclerosis patients’ disability, a Phase 3 clinical trial indicates. The therapy reduced the risk of disability progression in patients with secondary ... Read more

September 21, 2016September 21, 2016

#ECTRIMS2016 – Novartis’s Siponimod Appears to Slow SPMS Progression in Phase 3 Study

News

A presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress gave patients with progressive multiple sclerosis (MS) a reason for optimism, ... Read more

September 5, 2016September 4, 2016

MS Patient’s Pick of the Week’s News: Siponimod, Thymosin Patent, Orphan Drug, Lifestyle, and Lymphopenia Risk

Columns, What's Important Now -- An MS Column by Ian Franks

Here’s my Pick of the Week’s News, as published in Multiple Sclerosis News Today. Gilenya-like Therapy Shows Benefit in Secondary Progressive MS Patients in Phase 3 ... Read more

August 29, 2016October 31, 2016

Gilenya-like Therapy Shows Benefit in Secondary Progressive MS Patients in Phase 3 Trial

News

Patients with secondary progressive multiple sclerosis (SPMS) who were treated with BAF312 (siponimod), a sphingosine-1-phosphate (S1P) inhibitor, in a Phase 3 clinical trial showed a significantly reduced risk for disability ... Read more

September 12, 2014June 30, 2015

Novartis Presents Impressive Gilenya Updates at MSBoston 2014

Multiple Sclerosis News, News

This past Wednesday, September 10th, the largest, most anticipated multiple sclerosis (MS) convention — the 6th Joint ACTRIMS-ECTRIMS Triennial Meeting, MSBoston 2014 — kicked off with ... Read more

Pin It on Pinterest